source
- Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trialTeva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose…
- TScan Therapeutics cuts 75% of staff to focus on preclinical solid tumor programsTScan Therapeutics said it will cut about three quarters of its workforce after pausing its hematological and autoimmune programs. The company will shift resources to its preclinical solid tumor p…